TransCode Therapeutics (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. Conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, the study will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.
This trial represents a significant step for TransCode as it targets a critical unmet need: patients with minimal residual disease who are at high risk of relapse. By focusing on those who are circulating tumor DNA-positive, the study aims to intervene early before overt metastasis occurs. TTX-MC138 is designed to treat metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis. The Phase 2a trial will provide valuable data on the drug's efficacy and safety in this specific patient group.
The collaboration with Quantum Leap Healthcare Collaborative and the PRE-I-SPY platform underscores the innovative approach of this trial. The PRE-I-SPY platform is known for its adaptive trial designs that can accelerate the development of promising therapies. This partnership could potentially expedite the path to regulatory approval if TTX-MC138 shows positive results.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's lead candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The initiation of this trial is important because it addresses a significant gap in cancer care. Patients with minimal residual disease currently have limited options to prevent recurrence. If successful, TTX-MC138 could offer a new treatment paradigm for these patients, potentially reducing the risk of metastasis and improving survival outcomes.
For more information, visit the TransCode Therapeutics newsroom at https://ibn.fm/RNAZ. The full press release is available at https://ibn.fm/wuRri.
